KOSPIBiotech & Pharma145720

Dentium

₩39,700▲ 0.51%2026-11-18 close
Market Cap
₩342.4B
Turnover
₩700M
Volume
20K
Shares out.
8.6M
PER
18.1×
PBR
0.6×
EPS
₩2,170
Dividend Yield
1.52%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩600 per share · Prices as of the 2026-11-18 close

01

Report overview

Dentium: Testing Operating Profit Resilience Amid China Swings

Dentium's 2025 sales and profits both fell as China implant demand weakened, and although operating profit rose year on year in Q3 2026, the company swung to a net loss attributable to shareholders, so the durability of the China recovery and the bottom-line turn are the key points to track.

  1. 1

    2025 sales came to KRW 346.5 billion, down 15.0% from the prior year, and operating profit fell 34.9% to KRW 64.1 billion. Operating profit has declined for two consecutive years, from 2024 through 2025, after peaking in 2023.

  2. 2

    Q3 2026 operating profit rose 27.6% year on year to KRW 15.9 billion, while the company posted a net loss attributable to shareholders of KRW 7.94 billion after a profit a year earlier. Q3 sales were KRW 78.3 billion, up 0.1% from the prior-year quarter.

  3. 3

    Q3 2026 China sales reached KRW 39.6 billion, up 39% year on year (Pinpoint News, reported November 15, 2026). As of Q3 2025, China accounted for 42.2% of sales, still the largest single export market (MoneyToday, reported February 9, 2026).

  4. 4

    In Q3 2026, implant sales held up at KRW 63.1 billion, up 4% year on year, while the digital dentistry segment fell 30% to KRW 6.5 billion (based on Pinpoint News reporting).

  5. 5

    The SOFC fuel-cell business was expected, as of 2025 reporting, to start generating revenue in the second half of 2026, and it recorded an operating loss of KRW 1.3 billion in the first half of 2025 according to the half-year report (Business Post, 2025 reporting).

02

Business structure

Dentium is a dental equipment company whose core product is dental implants, and according to the company's own description it exports implant products to more than 77 countries. Beyond implants, it develops and produces bone-regeneration biomaterials such as bone graft materials and barrier membranes.

Of Q3 2026 sales of KRW 78.3 billion, the implant segment accounted for KRW 63.1 billion, up 4% year on year; the digital dentistry segment fell 30% to KRW 6.5 billion; and other businesses rose 6% to KRW 8.7 billion (Pinpoint News, reported November 15, 2026).

By region, China sales reached KRW 39.6 billion, up 39% year on year, and carried much of the quarter. As of Q3 2025, China made up 42.2% of sales, down from 51.4% in 2023 but still the largest single export market (MoneyToday, reported February 2026).

An analyst at a brokerage said exports to Asia excluding China and to Europe including Russia could keep growing strongly. Among domestic implant makers, Dentium is in the leading group, and in China it widened its sales network through new distributors and contracts with large dental groups.

After China's volume-based procurement (VBP) policy, price competition intensified in China, while easing dental treatment costs are broadening the demand base; the company says it is pairing its local production base with clinical education and digital equipment (SateEconomy, June 2026 reporting).

In new businesses, the company added a hydrogen fuel-cell business to its articles of incorporation in March 2024 and is building dedicated SOFC production equipment at the second plant of its Vietnamese subsidiary ICT VINA in Da Nang (Business Post, as of 2025 reporting).

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩78.2B₩12.5B15.9%
2025Q4₩109.1B₩26.5B24.3%
2026Q1₩71.4B₩15.9B22.2%
2026Q2₩89.3B₩14.7B16.4%
2026Q3₩78.3B₩15.9B20.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩355.9B₩125.7B₩86.1B35.3%23.0%80.8%
2023₩393.2B₩138.3B₩96.5B35.2%20.8%66.8%
2024₩407.8B₩98.5B₩72.7B24.2%13.1%61.6%
2025₩346.5B₩64.1B₩16.4B18.5%2.9%66.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-reported annual basis, sales rose from KRW 355.9 billion in 2022 to KRW 393.2 billion in 2023 (up 10.5%) and KRW 407.8 billion in 2024 (up 3.7%), the largest of the four years, before falling 15.0% to KRW 346.5 billion in 2025, the smallest.

Operating profit peaked at KRW 138.3 billion in 2023 (up 10.0%), then fell 28.8% to KRW 98.5 billion in 2024 and 34.9% to KRW 64.1 billion in 2025, declining for two consecutive years. The operating margin slipped from 35.3% in 2022 and 35.2% in 2023 to 24.2% in 2024 and 18.5% in 2025.

Profit attributable to shareholders peaked at KRW 96.5 billion in 2023, then fell 24.7% to KRW 72.7 billion in 2024 and 77.4% to KRW 16.4 billion in 2025, while net profit including non-controlling interests was KRW 16.3 billion in 2025.

Operating cash flow also fell from KRW 65 billion in 2023 to KRW 13.2 billion in 2025, so the earnings decline carried into weaker cash generation.

In the first half of 2025, sales of KRW 159.1 billion fell 18.1% year on year and operating profit of KRW 25.1 billion fell 46.5%, with weak consumption in China cited as the cause (Hankyung, August 2025 reporting).

Quarterly, Q4 2025 sales rose 39.5% sequentially to KRW 109.1 billion and operating profit rose 112.6% to KRW 26.5 billion, yet the company posted a net loss attributable to shareholders of KRW 4.98 billion that quarter, turning from profit to loss.

Q1 2026 sales were KRW 71.4 billion, operating profit KRW 15.9 billion and profit attributable to shareholders KRW 17.2 billion, a swing back to profit; Q2 2026 sales were KRW 89.3 billion, operating profit KRW 14.7 billion and profit attributable to shareholders KRW 13.9 billion.

Q3 2026 sales were KRW 78.3 billion and operating profit KRW 15.9 billion, improving on the operating line, but the company posted a net loss attributable to shareholders of KRW 7.94 billion, a swing from profit a year earlier.

The preliminary Q3 2026 disclosure released on November 10, 2026 showed a pre-tax loss of KRW 11.285 billion, so non-operating items weighed heavily despite positive operating profit. Profit attributable to shareholders over the latest four quarters totals KRW 18.2 billion.

05

Industry analysis

China is Dentium's largest sales base, so policy and demand in China's implant market largely determine its results. Since China's volume-based procurement (VBP) system, local implant pricing has been falling even as demand broadens (SateEconomy, June 2026 reporting).

In 2025, slowing demand in China and sharp profit compression under the VBP policy hit the results of major domestic implant makers together.

Operating results of the top three domestic implant companies all deteriorated in the first half of 2025, with weak local consumption in China cited as the cause (Hankyung, August 2025 reporting).

In a February 2026 report, MoneyToday said that in 2026, when China flagged a second round of VBP, Dentium, which depends heavily on China, would face a difficult year, while an analyst expected its exports to Asia excluding China and to Europe including Russia to keep growing strongly.

Brokerage estimates also suggested that China sales at one smaller domestic implant competitor would rise more than 80% in 2025 (MoneyToday, February 2026). Reporting on Q3 2026 results attributed the sales increase to a recovery in Chinese implant demand and expanded product supply (Pinpoint News, November 15, 2026).

If that reading holds, demand is returning after a policy shock, but how far pricing has recovered remains a variable still to be determined.

06

Outlook

The first variable is the timing and pricing terms of China's second round of VBP. MoneyToday reported in February 2026 that China had flagged a second VBP round, and its scope and price conditions remain items to confirm in follow-up announcements.

The second is whether the China sales recovery lasts, since a single quarter of 39% growth is too early to establish a trend.

The third is revenue from the SOFC fuel-cell business: Business Post's 2025 reporting expected the dedicated SOFC equipment at the second plant of the Vietnamese subsidiary to begin generating revenue in the second half of 2026 alongside mass production, and the company then expected revenue to start in that half.

The fourth is overseas expansion: at the Sinodental 2026 show in Beijing in June 2026, the company presented implants, CT, bone substitutes and education programs together, and in July and August 2026 it held academic congresses and its own seminar in India (Dental News, August 2026 reporting).

The fifth is the digital dentistry segment, which fell 30% to KRW 6.5 billion in Q3 2026; commentary holds that a recovery in related product sales could complement the implant-centered structure (Pinpoint News, November 15, 2026).

In the 2026 annual report, the next regular filing, the full-year operating margin and profit attributable to shareholders will be the next confirmation points.

07

Valuation

PER
18.1×
PBR
0.6×
ROE
3.3%
EPS
₩2,170
BPS
₩66,057
Dividend per share
₩600

The current share price can be read along two axes, net assets and earnings. The price-to-book ratio sits below 1x, which means the shares trade at a discount to net asset value.

At the end of 2025, total equity was KRW 561.2 billion, equity attributable to shareholders was KRW 562.4 billion, and total liabilities were KRW 371.6 billion. The debt-to-equity ratio fell from 80.8% in 2022 to 66.2% in 2025, though it edged up from 61.6% in 2024.

On earnings, profit attributable to shareholders over the latest four quarters totals KRW 18.2 billion, low compared with KRW 96.5 billion for full-year 2023. With earnings this reduced, earnings-based multiples move sharply with the pace of recovery, so they should be read alongside the quarterly trend.

Operating profit held in a range of KRW 14.7 billion to KRW 15.9 billion from Q1 to Q3 2026, but profit attributable to shareholders turned to a loss in Q3 2026, so the operating and bottom-line trends diverge.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

China sales rebound and operating profit gains

Q3 2026 China sales reached KRW 39.6 billion, up 39% year on year, and operating profit rose 27.6% to KRW 15.9 billion in the same quarter. The operating margin was reported at 20.3% (Pinpoint News, reported November 15, 2026).

Operating profit held between KRW 14.7 billion and KRW 15.9 billion from Q1 to Q3 2026, which supporters cite as evidence that earnings held up even while sales flattened.

Balance sheet and cash base

The debt-to-equity ratio declined from 80.8% in 2022 to 66.2% in 2025, and at the end of 2025 total equity stood at KRW 561.2 billion with equity attributable to shareholders at KRW 562.4 billion. Profit attributable to shareholders was positive in Q1 and Q2 2026, at KRW 17.2 billion and KRW 13.9 billion respectively. Supporters point to this sizable equity base as a cushion behind the earnings.

Overseas network and diversification

The company exports implants to more than 77 countries and widened its local reach through the Sinodental show in Beijing in June 2026 and academic events in India in July and August 2026.

The SOFC fuel-cell business is building equipment at the second plant of its Vietnamese subsidiary, and as of 2025 reporting, revenue was expected to start in the second half of 2026. Supporters argue that if this business takes hold, it could complement the implant-centered structure.

09

Bear factors

Heavy China dependence and policy uncertainty

As of Q3 2025, China accounted for 42.2% of sales, still the largest share. MoneyToday reported in February 2026 that with a second VBP round flagged, a company so reliant on China would face a difficult year.

Price competition in China has intensified, and whether one quarter of recovery offsets pricing changes will become clear from the trend in subsequent quarters.

Swing to net loss and non-operating drag

Q3 2026 showed a net loss attributable to shareholders of KRW 7.94 billion, a swing from profit a year earlier. The pre-tax loss for the same quarter was KRW 11.285 billion in the preliminary disclosure (Vegan News, November 2026 reporting).

Profit attributable to shareholders fell 77.4% to KRW 16.4 billion in 2025, and the latest four quarters total only KRW 18.2 billion.

New-business losses and a shrinking segment

Sales in the digital dentistry segment fell 30% to KRW 6.5 billion in Q3 2026 (Pinpoint News, reported November 15, 2026).

The hydrogen business recorded an operating loss of KRW 2.5 billion in 2024 with no revenue, and it lost KRW 1.3 billion in the first half of 2025 according to the half-year report (Business Post, 2025 reporting). Heavier spending outside the core implant business could add to earnings volatility.

10

Risk factors

China policy and pricing risk

Bid prices and volumes could change depending on the detailed terms of China's VBP policy and the timing of the second round. In 2025, slowing Chinese economic activity and VBP pricing together reduced profitability (MoneyToday, February 2026 reporting). Because China makes up a large share of sales, policy changes flow quickly into revenue and margins.

Diversification investment risk

The hydrogen fuel-cell business has continued to post operating losses ahead of revenue generation. As the preliminary Q3 2026 pre-tax loss showed, non-operating burdens can strongly swing net profit. If mass-production schedules slip, the timing of returns on this investment would also be pushed back.

Governance and related-party issues

A 2025 Business Post report pointed to a growing burden on the company tied to hydrogen investment, citing support provided to a company owned by the controlling shareholder. Market attention to related-party dealings can weigh on governance assessments. The effect of this issue on results is a matter for the company's filings to clarify.

11

What to watch next

  1. Date of the second VBP announcement (TBD)

    Once scope and price terms are set, the impact on China sales mix and margins will become direct. The question is whether the 39% rise in Q3 2026 China sales holds after the policy takes effect.

  2. Around early February 2027 (date TBD)

    This is the expected timing of the full-year 2026 preliminary results, including Q4 2026. Past reporting described Q4 as the implant peak season, and Q4 sales and operating profit will shape the full-year operating margin trend.

  3. By March 31, 2027

    This is the filing deadline for the 2026 annual report. The full-year operating margin, profit attributable to shareholders, and hydrogen business results will be fixed as regular-filing figures.

  4. By May 15, 2027

    This is the filing deadline for the Q1 2027 quarterly report. It is when the price effects of a second VBP round and China sales trends would first appear in quarterly figures.

12

Overall view

Dentium exports dental implants, and China is by far its largest sales market. On a DART-reported basis, sales peaked at KRW 407.8 billion in 2024 before falling to KRW 346.5 billion in 2025, while operating profit fell from a peak of KRW 138.3 billion in 2023 to KRW 64.1 billion in 2025.

Weaker consumption in China and the VBP policy are cited as the background to the 2025 profit decline. Quarterly sales moved between KRW 71.4 billion and KRW 89.3 billion in 2026, and operating profit held between KRW 14.7 billion and KRW 15.9 billion.

In Q3 2026, China sales rose 39% and operating profit rose 27.6%, but the company posted a net loss attributable to shareholders of KRW 7.94 billion, so the operating and bottom-line directions diverged.

Positive factors are signs of a China recovery, a wider overseas sales network, and diversification through the hydrogen business; negative factors are China policy risk, a net loss driven by non-operating burdens, and losses in the new business.

On valuation, the price-to-book ratio is below 1x and recent earnings are lower than in prior years. The next confirmation points are the terms of the second VBP round and the full-year 2026 operating margin and profit attributable to shareholders in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. vegannews.co.kr
  2. pinpointnews.co.kr
  3. mydaily.co.kr
  4. edaily.co.kr
  5. infostockdaily.co.kr
  6. ket.kr
  7. tradingkey.com
  8. tradingkey.com
  9. mt.co.kr
  10. edaily.co.kr
  11. sateconomy.co.kr
  12. edaily.co.kr
  13. dentium.career.greetinghr.com
  14. dentalnews.or.kr
  15. hankyung.com
  16. businesspost.co.kr
  17. splant.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis